肝门高位切除并肝门空肠吻合术在肝门部胆管癌治疗中的应用
发布时间：2021-01-29 05:06
目的探讨肝门高位切除并肝门空肠吻合术在肝门部胆管癌治疗中的应用。材料和方法 对56例术前诊断为肝门部胆管癌的病人进行了详细评估并进行外科手术。术前病人均进行了腹部超声、强化CT、及（或）MRCP检查,以确定病变的部位、侵及的范围、血管受侵的情况、有无远处转移等。血总胆红素超过400 μmol/L及（或）Child分级B级以下的病人行PTCD及胆汁回输,必要时给以肠内或肠外营养。分析临床资料,观察肝门高位切除并肝门空肠吻合术在肝门部胆管癌治疗效果。结果 51例病人行肝门高位切除并肝门空肠吻合术,5例病人因腹腔内转移术中行穿刺置管内引流术。术后病人血胆红素、谷丙转氨酶、谷草转氨酶明显下降。16例病人同时进行左（或右）半肝切除,合并右肝动脉切除11例、门静脉部分切除4例。术后发生肝脓肿3例,1例合并胆漏的病人术后2个月死于肺部感染。其余病人随访三个月,基本恢复正常生活。结论 扩大的肝门高位切除并肝门空肠吻合术是治疗肝门部胆管癌有效手术方式。
【文章来源】：山东大学山东省 211工程院校 985工程院校 教育部直属院校
【文章页数】：88 页
【学位级别】：硕士
【文章目录】：
中文摘要
ABSTRACT
LIST OF ABBREVIATIONS
CHAPTER ONE PREFACE
1.1 Introduction
1.2 Aim
CHAPTER TWO LITERATURE REVIEW
2.1 Cholangiocarcinoma overview
2.2 Epidemiology
2.3 Aetiology
2.4 The prevalence of iCCA, pCCA and dCCA
2.5 Pathology
2.6 Pathogenesis
2.7 Classification of CCA
2.7.1 Intrahepatic cholangiocarcinoma （iCCA）
2.7.2 Perihilar cholangiocarcinoma （pCCA）
2.7.3 Distal cholangiocarcinoma （dCCA）
2.8 Diagnosis and clinical presentation
2.8.1 iCCA subtype
2.8.2 pCCA subtype
2.8.3 dCCA subtype
2.9 Management and therapy
2.9.1 iCCA
2.9.2 pCCA
2.9.3 dCCA
2.10 Cytotoxic chemotherapies
2.11 The role of radiation therapy
2.12 Appearance of molecular directed therapies
2.12.1 Molecular pathogenesis
2.12.2 Molecular targeting therapies
2.13 Epigenetic alteration therapeutics
2.14 Novel capable aimed therapies
2.15 Immunotherapies for cholangiocarcinoma
2.15.1 Immunotherapy in oncology
2.15.2 Reasons for and risks of immunotherapy in CCA
2.15.3 Biomarkers of candidates in response to immunotherapy
2.15.4 Emerging clinical data on immune targeted therapies in CCA
CHAPTER THREE Methods
3.1 Patient's Information
3.2 Surgical Procedure
3.3 Post-operative management
CHAPTER FOUR Results
CHAPTER FIVE DISCUSSION AND CONCLUSION
5.1 Discussion
5.2 Conclusion
REFERENCES
PUBLICATION
ACKNOWLEDGEMENTS
学位论文评阅及答辩情况表
本文编号：3006323
【文章来源】：山东大学山东省 211工程院校 985工程院校 教育部直属院校
【文章页数】：88 页
【学位级别】：硕士
【文章目录】：
中文摘要
ABSTRACT
LIST OF ABBREVIATIONS
CHAPTER ONE PREFACE
1.1 Introduction
1.2 Aim
CHAPTER TWO LITERATURE REVIEW
2.1 Cholangiocarcinoma overview
2.2 Epidemiology
2.3 Aetiology
2.4 The prevalence of iCCA, pCCA and dCCA
2.5 Pathology
2.6 Pathogenesis
2.7 Classification of CCA
2.7.1 Intrahepatic cholangiocarcinoma （iCCA）
2.7.2 Perihilar cholangiocarcinoma （pCCA）
2.7.3 Distal cholangiocarcinoma （dCCA）
2.8 Diagnosis and clinical presentation
2.8.1 iCCA subtype
2.8.2 pCCA subtype
2.8.3 dCCA subtype
2.9 Management and therapy
2.9.1 iCCA
2.9.2 pCCA
2.9.3 dCCA
2.10 Cytotoxic chemotherapies
2.11 The role of radiation therapy
2.12 Appearance of molecular directed therapies
2.12.1 Molecular pathogenesis
2.12.2 Molecular targeting therapies
2.13 Epigenetic alteration therapeutics
2.14 Novel capable aimed therapies
2.15 Immunotherapies for cholangiocarcinoma
2.15.1 Immunotherapy in oncology
2.15.2 Reasons for and risks of immunotherapy in CCA
2.15.3 Biomarkers of candidates in response to immunotherapy
2.15.4 Emerging clinical data on immune targeted therapies in CCA
CHAPTER THREE Methods
3.1 Patient's Information
3.2 Surgical Procedure
3.3 Post-operative management
CHAPTER FOUR Results
CHAPTER FIVE DISCUSSION AND CONCLUSION
5.1 Discussion
5.2 Conclusion
REFERENCES
PUBLICATION
ACKNOWLEDGEMENTS
学位论文评阅及答辩情况表
本文编号：3006323
本文链接：https://www.wllwen.com/yixuelunwen/zlx/3006323.html
